 |
 |
|
|
|
National & World Ag News Headlines |
 |
Bayer to Acquire UK-Based Biotech KaNDy Therapeutics
USAgNet - 08/12/2020
Bayer and KaNDy Therapeutics Ltd. announced that Bayer will acquire the UK-based company to expand its drug development pipeline in women's healthcare. KaNDy Therapeutics Ltd. recently completed and published the Phase IIb dose range finding
study results for its' investigational compound, NT-814, a potential first in class, orally administered once-daily, neurokinin-1,3 receptor antagonist which showed positive findings for the treatment of moderate to severe vasomotor symptoms due to menopause.
The start of Phase III clinical trial is expected for 2021. Once approved, the compound could generate peak sales potential of more than €1 billion globally.
Up to 75% of women, over the age of 50, going through menopausal transition, experience menopausal vasomotor symptoms. These symptoms can be debilitating for several years for those affected and may result in significant incremental healthcare and
economic costs.
Under the terms of the agreement Bayer will pay an upfront consideration of $425 million, potential milestone payments of up to $450 million until launch followed by potential additional triple digit million sales milestone payments. Closing is subject to customary
conditions, in particular anti-trust approval, and is expected by September 2020.
"As a leader in Women's Health, Bayer is focused on providing new options for women and their healthcare needs," said Dr. Sebastian Guth, Bayer's president of pharmaceuticals, Americas Region. "This acquisition is another testament to our commitment to the
health of women, which not only broadens our pipeline, but has the potential, if approved, to deliver a new treatment option that could have a meaningful impact on women's lives."
"Bayer has been our preferred partner due to its leading position in the area of women's healthcare", said Dr. Mary Kerr, co-founder and CEO of KaNDy.. "We believe that under the ownership of Bayer, this potential first in class medicine can be optimally
developed to become an important non-hormonal treatment option for women suffering vasomotor symptoms due to menopause."
The acquisition of KaNDy is another important milestone in augmenting Bayer's own women's healthcare portfolio through strategic collaborations and agreements. Earlier in 2020, Bayer announced the expansion of its partnership with Evotec with a new
five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS), the most frequent endocrine disorder in pre-menopausal women. Also, in January 2020, Bayer signed an exclusive license
agreement with Dare Bioscience for the U.S. market, focused on its investigational, hormone-free, monthly vaginal contraceptive currently in clinical development for the prevention of pregnancy.
|
 |
|
 |
|
Copyright © 2024 - Farms.com. All Rights Reserved. |
 |
|
